KR101965025B1 - 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 - Google Patents

피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 Download PDF

Info

Publication number
KR101965025B1
KR101965025B1 KR1020147028071A KR20147028071A KR101965025B1 KR 101965025 B1 KR101965025 B1 KR 101965025B1 KR 1020147028071 A KR1020147028071 A KR 1020147028071A KR 20147028071 A KR20147028071 A KR 20147028071A KR 101965025 B1 KR101965025 B1 KR 101965025B1
Authority
KR
South Korea
Prior art keywords
mmol
delete delete
pyrimidin
pyrazolo
hydrocarbyl
Prior art date
Application number
KR1020147028071A
Other languages
English (en)
Korean (ko)
Other versions
KR20140138864A (ko
Inventor
잉지 비
케네스 고든 카슨
지오바니 시안체타
마이클 앨런 그린
고드윈 쿠미
앨런 메인
율리안 장
글렌 그레고리 지프
Original Assignee
렉시컨 파마슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 렉시컨 파마슈티컬스 인코퍼레이티드 filed Critical 렉시컨 파마슈티컬스 인코퍼레이티드
Publication of KR20140138864A publication Critical patent/KR20140138864A/ko
Application granted granted Critical
Publication of KR101965025B1 publication Critical patent/KR101965025B1/ko

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147028071A 2012-03-09 2013-03-05 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 KR101965025B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608765P 2012-03-09 2012-03-09
US61/608,765 2012-03-09
PCT/US2013/029056 WO2013134228A1 (en) 2012-03-09 2013-03-05 PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE

Publications (2)

Publication Number Publication Date
KR20140138864A KR20140138864A (ko) 2014-12-04
KR101965025B1 true KR101965025B1 (ko) 2019-04-02

Family

ID=47892052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028071A KR101965025B1 (ko) 2012-03-09 2013-03-05 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법

Country Status (26)

Country Link
US (3) US8946415B2 (US07585860-20090908-C00112.png)
EP (1) EP2834243B1 (US07585860-20090908-C00112.png)
JP (1) JP6418950B2 (US07585860-20090908-C00112.png)
KR (1) KR101965025B1 (US07585860-20090908-C00112.png)
CN (1) CN104302649B (US07585860-20090908-C00112.png)
AR (1) AR090292A1 (US07585860-20090908-C00112.png)
AU (1) AU2013230128B2 (US07585860-20090908-C00112.png)
BR (1) BR112014022000A8 (US07585860-20090908-C00112.png)
CA (1) CA2866143C (US07585860-20090908-C00112.png)
DK (1) DK2834243T3 (US07585860-20090908-C00112.png)
ES (1) ES2676224T3 (US07585860-20090908-C00112.png)
HK (1) HK1201257A1 (US07585860-20090908-C00112.png)
HU (1) HUE038786T2 (US07585860-20090908-C00112.png)
IL (1) IL234486A (US07585860-20090908-C00112.png)
IN (1) IN2014DN07384A (US07585860-20090908-C00112.png)
MX (1) MX345830B (US07585860-20090908-C00112.png)
NZ (1) NZ630721A (US07585860-20090908-C00112.png)
PL (1) PL2834243T3 (US07585860-20090908-C00112.png)
PT (1) PT2834243T (US07585860-20090908-C00112.png)
RU (1) RU2014140735A (US07585860-20090908-C00112.png)
SG (1) SG11201405561RA (US07585860-20090908-C00112.png)
TR (1) TR201808280T4 (US07585860-20090908-C00112.png)
TW (1) TW201341386A (US07585860-20090908-C00112.png)
UY (1) UY34668A (US07585860-20090908-C00112.png)
WO (1) WO2013134228A1 (US07585860-20090908-C00112.png)
ZA (1) ZA201406149B (US07585860-20090908-C00112.png)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
HUE045208T2 (hu) 2014-01-24 2019-12-30 Turning Point Therapeutics Inc Diaril makrociklusok mint protein kinázok modulátorai
ES2701903T3 (es) * 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
US9701681B2 (en) * 2014-12-15 2017-07-11 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as Trk inhibitors
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
WO2017004342A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
CN113354653A (zh) 2015-07-06 2021-09-07 特普医药公司 二芳基大环多晶型物及其制备方法
DK3325488T3 (da) 2015-07-21 2020-09-14 Turning Point Therapeutics Inc Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
JP6872541B2 (ja) * 2015-11-02 2021-05-19 ヤンセン ファーマシューティカ エヌ.ベー. [1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物
CN109715165A (zh) 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
SG11201903892UA (en) * 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
ES2912264T3 (es) 2016-11-02 2022-05-25 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
ES2855032T3 (es) 2016-11-02 2021-09-23 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ, インコーポレイテッド Tyk2阻害剤およびその使用方法
WO2019023417A1 (en) 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
US11453672B2 (en) 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
JP2022503932A (ja) * 2018-09-27 2022-01-12 フォチョン・ファーマシューティカルズ・リミテッド Retキナーゼ阻害剤としての置換イミダゾ[1,2-a]ピリジン及び[1,2,4]トリアゾロ[1,5-a]ピリジン化合物
AU2019360941A1 (en) * 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CA3175970A1 (en) 2020-04-21 2021-10-28 Suma GOPINATHAN Aak1 inhibitors for use in treating viral infections
WO2021216454A1 (en) * 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
US11478733B2 (en) 2020-11-24 2022-10-25 Caterpillar Inc. Filter interlock with tabs mating with a pedestal or a housing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ[1,5−a]ピリミジン化合物
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US8507488B2 (en) * 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PL3372605T3 (pl) * 2008-10-22 2022-03-07 Array Biopharma Inc. Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2011087999A1 (en) 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
JP6105578B2 (ja) * 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ, インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
MX347917B (es) 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ1の阻害
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法

Also Published As

Publication number Publication date
CA2866143C (en) 2020-08-04
CN104302649A (zh) 2015-01-21
PT2834243T (pt) 2018-08-01
KR20140138864A (ko) 2014-12-04
US8946415B2 (en) 2015-02-03
EP2834243A1 (en) 2015-02-11
DK2834243T3 (en) 2018-07-23
AU2013230128B2 (en) 2017-08-17
CA2866143A1 (en) 2013-09-12
CN104302649B (zh) 2017-06-23
AR090292A1 (es) 2014-11-05
US20130253194A1 (en) 2013-09-26
US9403832B2 (en) 2016-08-02
US20170129896A1 (en) 2017-05-11
UY34668A (es) 2013-10-31
NZ630721A (en) 2016-12-23
JP6418950B2 (ja) 2018-11-07
MX2014010589A (es) 2014-09-18
IN2014DN07384A (US07585860-20090908-C00112.png) 2015-04-24
TW201341386A (zh) 2013-10-16
ZA201406149B (en) 2016-06-29
HK1201257A1 (en) 2015-08-28
BR112014022000A8 (pt) 2021-06-15
RU2014140735A (ru) 2016-04-27
BR112014022000A2 (pt) 2017-06-20
PL2834243T3 (pl) 2018-09-28
SG11201405561RA (en) 2014-10-30
HUE038786T2 (hu) 2018-11-28
AU2013230128A1 (en) 2014-09-25
TR201808280T4 (tr) 2018-07-23
JP2015509535A (ja) 2015-03-30
ES2676224T3 (es) 2018-07-17
EP2834243B1 (en) 2018-04-25
US20150183792A1 (en) 2015-07-02
WO2013134228A1 (en) 2013-09-12
MX345830B (es) 2017-02-17
IL234486A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
KR101965025B1 (ko) 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법
US8969565B2 (en) Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
US9862724B2 (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
US20150183791A1 (en) IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
JP6553081B2 (ja) アダプター関連キナーゼ1の阻害剤、それを含む組成物、及びその使用方法

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant